Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis
Uma Sriram(Temple University), Jorge R. Oksenberg(University of California, San Francisco), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Pablo Villoslada(University of California, San Francisco), Stacy J. Caillier(University of California, San Francisco), Jordi Río(Universitat Autònoma de Barcelona), Lisa F. Barcellos(University of California, San Francisco), Alicia Stillman(University of California, San Francisco), Stephen L. Hauser(University of California, San Francisco), Sergio E. Baranzini(University of California, San Francisco)
Cited by 78
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k